Medical trials at Aurora Research Institute uncover lifesaving news for leukemia patientsA prolonged life and fewer side effects are among the benefits for leukemia patients on a specific drug regimen, according to two new clinical trials.
The breakthrough findings are expected to immediately change the treatment for patients with leukemia.
Both trials Aurora Research Institute studied the anticancer drug called ibrutinib for treating chronic lymphocytic leukemia (CLL).
“CLL is the most common leukemia in adults in Western count ries,” said Dr. Rubina Qamar, the principal investigator… (Source: bizjournals.com Health Care:Biotechnology headlines)Source: bizjournals.com Health Care:Biotechnology headlines - April 29, 2019 Category: Biotechnology Authors: Advocate Aurora Health Source Type: news

Medical trials at Aurora Research Institute uncover lifesaving news for leukemia patientsA prolonged life and fewer side effects are among the benefits for leukemia patients on a specific drug regimen, according to two new clinical trials.
The breakthrough findings are expected to immediately change the treatment for patients with leukemia.
Both trials Aurora Research Institute studied the anticancer drug called ibrutinib for treating chronic lymphocytic leukemia (CLL).
“CLL is the most common leukemia in adults in Western count ries,” said Dr. Rubina Qamar, the principal investigator… (Source: bizjournals.com Health Care:Physician Practices headlines)Source: bizjournals.com Health Care:Physician Practices headlines - April 29, 2019 Category: American Health Authors: Advocate Aurora Health Source Type: news

Some Cancers Are Rising in Young People. Scientists Think They Know WhyThe rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute.
Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endom...Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be the Reason WhyThe rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute.
Obesity rates have been rising across age groups for years. According to the latest federal numbers, almost 36% of American adults ages 20-39 are obese, and that number may soon be even higher. Recent research suggests that if obesity trends continue, 57% of children in the U.S. will be obese by the time they turn 35.
Rates ...Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be WhyThe rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute.
Obesity rates have been rising across age groups for years. According to the latest federal numbers, almost 36% of American adults ages 20-39 are obese, and that number may soon be even higher. Recent research suggests that if obesity trends continue, 57% of children in the U.S. will be obese by the time they turn 35.
Rates ...Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Patients with chronic myeloid leukemia can manage their anxiety with bitter orange essential oil(Natural News) Patients with chronic myeloid leukemia, who often suffer from anxiety, may find relief in bitter orange (Citrus aurantium L.) essential oil. A study published in the journal Phytotherapy Research reported that breathing in bitter orange essential oil could reduce anxiety in people with chronic myeloid leukemia, suggesting that it has potential use as... (Source: NaturalNews.com)Source: NaturalNews.com - January 21, 2019 Category: Consumer Health News Source Type: news

New leukemia drug is more effective and easier to use(Loyola University Health System) A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug is taken as a pill once a day -- much more convenient than the standard treatment requiring the patient to come in three times a month for infusions and an injection. (Source: EurekAlert! - Medicine and Health)Source: EurekAlert! - Medicine and Health - January 11, 2019 Category: International Medicine & Public Health Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemiaRoche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemiaRoche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Experts present new recommendations on 'overlapping' type of leukemia(Wolters Kluwer Health) Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management. Joint recommendations on diagnosis and treatment of CMML from two European specialty societies were published today in HemaSphere, the official journal of the European Hematology Association (EHA). The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news

For Chronic Leukemia Patients, the News Just Got Even BetterSeveral chronic lymphocytic leukemia (CLL) patients at the Wilmot Cancer Institute took part in two groundbreaking, nationwide phase 3 studies that are changing the way doctors treat the disease. The positive results are being reported this weekend at the 2018 American Society of Hematology (ASH) annual meeting — and will immediately impact CLL patients in the Rochester region and across the U.S., said Paul Barr, M.D., director of Wilmot’s Clinical Trials Office. (Source: University of Rochester Medical Center Press Releases)Source: University of Rochester Medical Center Press Releases - November 29, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

FDA approves new treatment for patients with acute myeloid leukemiaThe U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: World Pharma News)Source: World Pharma News - November 22, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA approves new treatment for patients with acute myeloid leukemiaThe FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: Food and Drug Administration)Source: Food and Drug Administration - November 21, 2018 Category: American Health Source Type: news

Researchers in Barcelona awarded with one of the most prestigious EU grants to unravel CLL(Center for Genomic Regulation) The European Research Council today announced the results of the 2018 ERC Synergy Grants Call. A project, the BCLL@las, of four research groups from the Centro Nacional de An á lisis Gen ó mico of the Centre for Genomic Regulation, and the Institut d'Investigacions Biom è diques August Pi i Sunyer have received this prestigious grant to unravel the genomics and epigenomics of chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis. (Source: EurekAlert! - Cancer)Source: EurekAlert! - Cancer - October 26, 2018 Category: Cancer & Oncology Source Type: news